Yomeishu Seizo Co.,Ltd. Stocks

¥ 4045Last Updated 27.03.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

¥ 351.04M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 4045
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Yomeishu Seizo Co., Ltd. produces and sells herbal liqueurs and pharmaceutical products in Japan, Hong Kong, Malaysia, Singapore, and Taiwan. It offers Yomeishu, an herbal liqueur; ginger, ginseng, honey, and medicinal liqueur; fruit and herbs liqueur; Kanomori and Kanoshizuku gin; and craft gin cocktail products. The company also provides Yomeishu cough drops; Yomeishu Seizo Amazake; Herb-no-Megumi; Ururu vinegar drinks; ginger black vinegar drinks; and dilution type black vinegar drinks. In addition, it offers Koken Seisai designated quasi-pharmaceutical and health products through the mail order site www.yomeishu-online.jp. Further, the company operates CLASUWA, a commercial complex; rents/leases real estate properties; manages restaurants and shops; and generates, supplies, and sells electricity through natural energy. Yomeishu Seizo Co., Ltd. was incorporated in 1923 and is headquartered in Tokyo, Japan.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks